239 related articles for article (PubMed ID: 11948143)
1. Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma.
Mohammad R; Abubakr Y; Dan M; Aboukameel A; Chow C; Mohamed A; Hamdy N; Al-Katib A
Clin Cancer Res; 2002 Apr; 8(4):1277-83. PubMed ID: 11948143
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of treatment with antisense oligonucleotides complementary to immunoglobulin sequences of bcl-2/immunoglobulin fusion transcript in a t(14;18) human lymphoma-scid mouse model.
Smith MR; Xie T; Zhou ZZ; Joshi I
Clin Cancer Res; 2001 Feb; 7(2):400-6. PubMed ID: 11234896
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model.
Cotter FE; Johnson P; Hall P; Pocock C; al Mahdi N; Cowell JK; Morgan G
Oncogene; 1994 Oct; 9(10):3049-55. PubMed ID: 8084613
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL.
Smith MR; Abubakr Y; Mohammad R; Xie T; Hamdan M; al-Katib A
Cancer Gene Ther; 1995 Sep; 2(3):207-12. PubMed ID: 8528964
[TBL] [Abstract][Full Text] [Related]
5. A bcl-2/IgH antisense transcript deregulates bcl-2 gene expression in human follicular lymphoma t(14;18) cell lines.
Capaccioli S; Quattrone A; Schiavone N; Calastretti A; Copreni E; Bevilacqua A; Canti G; Gong L; Morelli S; Nicolin A
Oncogene; 1996 Jul; 13(1):105-15. PubMed ID: 8700536
[TBL] [Abstract][Full Text] [Related]
6. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
Tortora G; Caputo R; Damiano V; Bianco R; Fontanini G; Cuccato S; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2001 Aug; 7(8):2537-44. PubMed ID: 11489837
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
8. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.
Thallinger C; Wolschek MF; Maierhofer H; Skvara H; Pehamberger H; Monia BP; Jansen B; Wacheck V; Selzer E
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4185-91. PubMed ID: 15217956
[TBL] [Abstract][Full Text] [Related]
9. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
[TBL] [Abstract][Full Text] [Related]
10. Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model.
Wacheck V; Heere-Ress E; Halaschek-Wiener J; Lucas T; Meyer H; Eichler HG; Jansen B
J Mol Med (Berl); 2001 Oct; 79(10):587-93. PubMed ID: 11692156
[TBL] [Abstract][Full Text] [Related]
11. Establishment and comprehensive analysis of a new human transformed follicular lymphoma B cell line, Tat-1.
Denyssevych T; Lestou VS; Knesevich S; Robichaud M; Salski C; Tan R; Gascoyne RD; Horsman DE; Mayer LD
Leukemia; 2002 Feb; 16(2):276-83. PubMed ID: 11840295
[TBL] [Abstract][Full Text] [Related]
12. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
Benimetskaya L; Ayyanar K; Kornblum N; Castanotto D; Rossi J; Wu S; Lai J; Brown BD; Popova N; Miller P; McMicken H; Chen Y; Stein CA
Clin Cancer Res; 2006 Aug; 12(16):4940-8. PubMed ID: 16914583
[TBL] [Abstract][Full Text] [Related]
14. Oligonucleotides induce apoptosis restricted to the t(14;18) DHL-4 cell line.
Morelli S; Alama A; Quattrone A; Gong L; Copreni E; Canti G; Nicolin A
Anticancer Drug Des; 1996 Jan; 11(1):1-14. PubMed ID: 8639245
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
de Kroon JF; de Paus RA; Kluin-Nelemans HC; Kluin PM; van Bergen CA; Munro AJ; Hale G; Willemze R; Falkenburg JH
Exp Hematol; 1996 Jul; 24(8):919-26. PubMed ID: 8690051
[TBL] [Abstract][Full Text] [Related]
16. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
[TBL] [Abstract][Full Text] [Related]
17. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
[TBL] [Abstract][Full Text] [Related]
18. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
19. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.
Hu Y; Bebb G; Tan S; Ng R; Yan H; Sartor JR; Mayer LD; Bally MB
Clin Cancer Res; 2004 Nov; 10(22):7662-70. PubMed ID: 15569999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]